Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab

Merkel cell carcinoma has historically had dismal prognosis with limited cytotoxic chemotherapy options that provide durable control of metastatic disease. The advent of anti-programmed death protein (anti-PD1)/anti-programmed death-ligand 1 (anti-PD-L1) directed immunotherapy has shown initial prom...

Full description

Bibliographic Details
Main Authors: Brooke C. Bloom, Alexander Augustyn, Todd A. Pezzi, Hari Menon, Lauren L. Mayo, Shalin J. Shah, David L. Schwartz, Steven J. Chmura, Faye M. Johnson, James W. Welsh, Stephen G. Chun
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Oncology
Subjects:
Merkel cell carcinoma
radiation
abscopal
PD-1
PD-L1
immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00223/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00223/full

Similar Items